AOD-9604 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What AOD-9604 Does & How It Works

What It Does - Functional Outcomes

• Accelerates breakdown of stored fat in adipose tissue, releasing free fatty acids for use as energy
• Inhibits the formation of new fat from excess dietary carbohydrates - reducing fat accumulation independent of caloric intake in some models
• Increases the rate at which the body burns fat for fuel, including through enhanced fat oxidation in adipose tissue
• Produces these metabolic effects without raising IGF-1 levels, disrupting blood glucose, or triggering the growth-promoting cascade associated with full-length human growth hormone
• In secondary research applications, promotes cartilage regeneration and collagen production in joint tissue models

How It Works - Mechanism of Action

Beta-3 Adrenergic Receptor Upregulation (Evidence: Animal)

In obese animal models, AOD-9604 restored depressed beta-3 adrenergic receptor expression in white adipose tissue to levels comparable with lean controls. Beta-3 adrenergic receptors sit on the surface of fat cells and act as molecular on-switches for fat breakdown. Once activated, they trigger a signaling chain - elevated cyclic AMP, activated Protein Kinase A, phosphorylated Hormone-Sensitive Lipase - that drives stored triglycerides to release as free fatty acids. Knockout mouse experiments showed that acute single-dose effects on fat oxidation still occurred even without functional beta-3 receptors, which means the receptor upregulation is a downstream consequence of AOD-9604's signaling, not the compound's initial binding target.

Direct Lipolysis and Lipogenesis Inhibition (Evidence: Animal and ex vivo human tissue)

AOD-9604 directly stimulates triglyceride breakdown in adipocytes while simultaneously blocking the conversion of non-fat substrates into new fat storage. The lipolytic effect was confirmed in human adipose tissue using ex vivo experiments: actual human fat tissue samples showing a threefold increase in glycerol release, which is a direct quantitative marker of triglyceride breakdown. These two mechanisms - breaking down existing fat while preventing new fat formation - work in parallel, which is part of what made AOD-9604 an attractive research target for metabolic applications.

AMPK Pathway Involvement and Fat Oxidation (Evidence: Animal models)

Lipolytic effects in rodent models involve AMP-activated protein kinase (AMPK) pathways, which is a central cellular energy-sensing system that shifts cells from energy storage toward energy utilization when activated. AMPK activation suppresses fat synthesis and promotes fat oxidation simultaneously. Brown adipose tissue uncoupling, where fat tissue generates heat rather than ATP, has been proposed as a contributing mechanism to the observed whole-body energy expenditure increases. Metabolic effects on lipid utilization have been documented to persist beyond the compound's brief plasma clearance, suggesting that downstream second-messenger cascades continue running after the peptide itself has gone.

IGF-1-Independent Action (Evidence: Human clinical trials)

AOD-9604 does not bind growth hormone receptors, does not elevate serum IGF-1 at any dose tested, and produces no growth-promoting effects on any measured tissue. This was confirmed across all six human clinical trials. It achieves its metabolic effects through an entirely separate pathway from full-length growth hormone's primary receptor signaling. This IGF-1 independence is the defining feature that separates AOD-9604 from full-length hGH and from growth hormone secretagogues, removing the metabolic complications - insulin resistance, edema, tissue overgrowth - that those compounds carry.

Secondary Regenerative Effects (Evidence: In vitro)

Cell culture studies showed that AOD-9604 promotes differentiation of adipose-derived mesenchymal stem cells into bone-forming cells, increases proteoglycan and collagen production in bovine chondrocyte cultures, and enhances myoblast differentiation. These effects operate through a mechanism distinct from the lipolytic signaling pathway, and the specific receptor target has not been characterized. This regenerative application was not anticipated when the compound was developed as a weight-loss drug and represents an independently emerging research direction.

AOD-9604 Molecular Profile

Structure reference: View on PubChem CID 71300630 - Publishing team: retrieve 2D structure image from this link.

Structural notes: The disulfide bridge between the two cysteine residues at positions 7 and 14 is a key architectural feature. It creates a cyclic region within the otherwise linear chain, confers resistance to enzymatic degradation, and is the primary structural basis for the compound's unusual resistance to gastric acid. The N-terminal tyrosine was added intentionally by the Monash University research team to improve stability and extend effective biological activity - this modification is what distinguishes AOD-9604 from the raw, unmodified hGH C-terminal sequence.

AOD-9604 Uses & Benefits

Fat Loss and Body Recomposition

AOD-9604 is most commonly researched and used in the context of fat metabolism, specifically targeting lipolysis in white adipose tissue, reducing lipogenesis, and improving fat oxidation efficiency. Users seeking this AOD-9604 peptide typically have body recomposition goals: reducing body fat percentage while preserving lean mass. The mechanism is directly suited to this application, targeting adipose tissue biology through beta-3 adrenergic and AMPK signaling without the metabolic disruption associated with full-length growth hormone. The Phase IIa human trial demonstrated 2.6 kg average weight loss versus 0.8 kg for placebo over 12 weeks at 1 mg/day - a meaningful signal, though one that did not replicate in the larger Phase III trial. (Evidence: Moderate - Heffernan et al., 2001, Endocrinology)

Metabolic Health and Insulin-Sensitivity Preservation

Because AOD-9604 produces no changes in IGF-1, glucose tolerance, or insulin sensitivity at studied doses, it is of interest to users seeking metabolic health support without the glycemic risks associated with growth hormone. Individuals with metabolic concerns who want fat-targeting properties without hormonal disruption represent a specific research population this compound was designed to serve. The confirmed absence of insulin sensitivity impairment across six controlled trials distinguishes it meaningfully from full-length hGH and from some other metabolic compounds. (Evidence: Moderate - human clinical safety data - Stier et al., 2013, Regulatory Toxicology and Pharmacology)

Joint and Cartilage Regeneration

Post-discontinuation research shifted toward joint applications after in vitro studies demonstrated that AOD-9604 promotes collagen and proteoglycan production in chondrocyte cultures. A rabbit osteoarthritis model using intra-articular injection showed improved cartilage morphology, better histopathological scores, and reduced lameness versus controls - with superior outcomes when combined with hyaluronic acid. This application is at an early research stage with no human clinical data, but the mechanistic basis is distinct from the lipolytic pathway and represents a genuinely separate research direction. Users with joint health goals sometimes include AOD-9604 in protocols alongside compounds with more established musculoskeletal evidence. (Evidence: Preliminary - animal model - Kwon & Park, 2015, Annals of Clinical and Laboratory Science)

Visceral Fat Targeting

The Phase IIa trial noted preferential reduction in abdominal and visceral fat in the AOD-9604 group compared to placebo, which is of particular interest given that visceral adiposity carries the highest metabolic risk. The compound's lipolytic mechanism appears to preferentially target obese adipocytes over lean fat cells in animal models, suggesting some degree of selectivity in where fat breakdown is stimulated. This visceral targeting effect was observed but not fully characterized in the human trial, and the Phase III trial did not confirm it as a primary finding. (Evidence: Preliminary - derived from Phase IIa data - Heffernan et al., 2001, Endocrinology)

Where This Guide Comes From

AOD-9604 Results & Timelines

Fat Loss and Body Recomposition

• Week 1-2: Most users report little to nothing perceptible at this stage. AOD-9604's mechanism operates through shifts in adipose tissue metabolism that develop over time rather than producing immediate noticeable effects. Some users note slightly reduced appetite in the early weeks, though this is not a documented mechanism.
• Week 3-6: Community protocol data begins to show changes in body composition for users who report measurable outcomes. Gradual fat loss without significant lean mass changes is the most commonly described pattern. Some users report improved energy levels during this window.
• Week 6-12: The range where most users in tracked protocols report meaningful body composition shifts, aligning with the 12-week Phase IIa clinical trial window where the primary efficacy signal was observed. The 2.6 kg average loss in the Phase IIa trial over 12 weeks gives a reference point for what clinically significant fat reduction looked like in the best human trial.
• Beyond 12 weeks: Some users run extended protocols to 16 weeks. No clinical data exists beyond 24 weeks, and the Phase III's 24-week protocol with intensive lifestyle intervention did not separate from placebo - suggesting that longer does not necessarily mean better for this compound.

Joint and Cartilage Support

• Week 1-4: No reliable timeline data for joint applications in humans. The rabbit model used a single intra-articular injection with outcomes assessed over weeks, not a chronic oral or subcutaneous dosing protocol. Users incorporating AOD-9604 for joint goals alongside other compounds make it difficult to isolate timelines.
• Week 4-12: Community anecdote for joint applications is thinner than for fat loss, and largely inseparable from the effects of co-administered compounds. Users should treat joint timeline expectations as genuinely unknown territory given the absence of human data.

How to Administer AOD-9604

Subcutaneous Injection (SubQ)

Subcutaneous injection is the most widely used administration route for AOD-9604 in current research protocols. Injection into the subcutaneous fat layer - commonly the abdomen, flank, or upper thigh - delivers the compound systemically with practical, reproducible dosing. SubQ administration offers more precise dose control than oral dosing, which is a key practical advantage in research contexts where consistent delivery matters. Absorption is slower than intravenous but appropriate for once-daily dosing schedules.

Intramuscular Injection (IM)

IM administration is not a standard documented route for AOD-9604 in published research. SubQ is the preferred injection route for this compound. IM injection is occasionally discussed in community protocols but is not supported by comparative pharmacokinetic data for this specific peptide.

Oral

AOD-9604 is one of the few peptides with confirmed oral bioavailability - an unusual property that most peptides do not share. The structural basis is the disulfide bridge between Cys7 and Cys14 combined with the N-terminal tyrosine modification, which together confer resistance to gastric acid and proteolytic degradation. Oral administration was used in both the Phase IIa and Phase III human clinical trials, providing real human evidence for the viability of this route. Despite confirmed oral activity, subcutaneous injection is more commonly used in current protocols because it offers more precise dose control and bypasses any variability in gastrointestinal absorption.

Intra-articular Injection

Intra-articular injection - directly into a joint space - was the administration route used in the Kwon and Park (2015) rabbit osteoarthritis study at 0.25 mg per joint. This is a research-specific route relevant only to cartilage and joint regeneration applications. It is not a general administration method for AOD-9604 metabolic protocols and requires clinical expertise for safe administration.

AOD-9604 Dosage & Cycle Length

Overall dosing range: 250 mcg to 1 mg per day - drawn from published clinical trial data and real-world research protocols; route and individual goals influence where someone lands within this range

How the goal shifts where you land:

• Low end of range (250-500 mcg): commonly associated with longer-duration protocols, maintenance-oriented use, and body recomposition goals where gradual fat loss over an extended cycle is the target
• Mid range (500-750 mcg): commonly associated with general fat loss and metabolic health protocols; represents the overlap between clinical trial dosing and community practice
• High end of range (750 mcg to 1 mg): the 1 mg/day dose produced the best weight loss result in the Phase IIa clinical trial - the dose where the strongest human efficacy signal was observed (Evidence: Moderate - human Phase IIa RCT)

One critical dosing note specific to AOD-9604: Higher doses are not more effective. The Phase IIa trial tested 10 mg/day alongside 1 mg/day and found the lower dose outperformed the higher one. This non-linear, paradoxical dose-response relationship is one of the more unusual pharmacological features of this compound. More is not better here - it may actually be counterproductive.

Frequency: Once daily in all published human clinical trial protocols

Cycle length: Clinical trials ran 12 weeks (Phase IIa) and 24 weeks (Phase III). Real-world protocols tracked in community documentation most commonly run 8-12 weeks, with some users extending to 16 weeks. The Phase III used the longer duration with intensive dietary and lifestyle intervention alongside the peptide.

Loading protocols: Not documented in published research for AOD-9604. No loading or frontloading approach has been established in the literature.

AOD-9604 Vial Sizes, Costs & Quality

Common vial sizes: 2 mg and 5 mg are the most standard vial sizes for AOD-9604 in the current research peptide market; 10 mg vials are available from some suppliers

Typical cost range: $40-$80 per vial for U.S.-manufactured research-grade AOD-9604 at current market pricing - varies by vial size, supplier, and purity documentation; 5 mg vials tend to offer better per-milligram value than 2 mg vials

Storage - lyophilized (dry powder):

• Temperature: Freeze at -20 degrees C for long-term storage
• Shelf life: Typically stable for 12-24 months when properly stored in lyophilized form
• Light sensitivity: Keep away from direct light; store in a dark environment

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C after reconstitution
• Use window: Typically 28-30 days once reconstituted, though some protocols recommend using within 21 days for best stability

Normal appearance after reconstitution: AOD-9604 should dissolve into a clear, colorless solution. Given its water solubility and the disulfide bridge structure, it typically reconstitutes cleanly without cloudiness or particulates when properly handled.

Signs of degradation: Heavy or persistent cloudiness beyond brief initial mixing turbulence, visible white chunks or floating particulates, yellowing or browning of the solution, or an unusual odor all indicate potential degradation. Degraded peptide should not be used.

Quality Considerations

Peptide synthesis is chemistry, and chemistry costs money. AOD-9604's disulfide bridge between Cys7 and Cys14 makes it more structurally complex than a simple linear peptide - proper formation of that bridge during synthesis requires controlled conditions and quality verification. When AOD-9604 is priced significantly below market norms, something in that process got cut: synthesis purity, purification steps, third-party testing, or all three. A large portion of what circulates online originates from overseas facilities with no standardized manufacturing controls, no independent purity verification, and no accountability if the vial contains the wrong concentration or contaminants. U.S.-manufactured research peptides come with documented synthesis standards, third-party certificates of analysis, and domestic accountability - you can verify what is in the vial. For a compound being injected, that verification is not optional.

AOD-9604 Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy: No specific data establishes AOD-9604 as safe in the context of active cancer. The compound does not appear to elevate IGF-1 or stimulate growth hormone receptors, which removes one typical oncological concern with GH-related compounds, but absence of IGF-1 elevation does not constitute a confirmed safety clearance in cancer contexts. Insufficient data to confirm safety in individuals with active malignancy.
• Hypersensitivity to any component of the preparation: Standard contraindication for synthetic peptides; avoid in individuals with documented hypersensitivity reactions to AOD-9604 or excipients used in reconstitution vehicles.
• Post-Phase III development termination: AOD-9604's clinical development was formally stopped in 2007. No ongoing clinical trials are actively generating updated safety data for specific comorbid populations.

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: No safety data exists for AOD-9604 in pregnant or breastfeeding individuals. Use is not recommended without medical supervision.
• Pediatric use: Not studied in pediatric populations. Not appropriate for use in children without medical supervision.
• Hepatic or renal impairment: Pharmacokinetic behavior in individuals with significant liver or kidney dysfunction has not been formally characterized in the published literature. Insufficient data to confirm safety in these populations.
• Metabolic syndrome with significant insulin dysregulation: While AOD-9604 has been confirmed not to impair insulin sensitivity at studied doses, the compound has not been specifically studied in populations with pre-existing severe insulin resistance or type 2 diabetes as a primary condition. Caution and medical supervision are warranted.

Red Flags - Stop Use and Seek Medical Attention If:

• Significant swelling, persistent pain, or unusual warmth at an injection site that does not resolve within 24-48 hours
• Signs of a systemic allergic reaction: widespread rash, difficulty breathing, facial or throat swelling
• Unusual or severe headache that develops after administration
• Significant changes in blood glucose levels or symptoms suggesting hypoglycemia or hyperglycemia
• Any symptom that feels disproportionate or unexpected relative to the mild side effect profile reported in clinical research

Drug and Compound Interactions

No specific drug interactions have been formally documented for AOD-9604 in the published literature, which reflects the limited pharmacological characterization of this compound rather than confirmed absence of interactions. Given its mechanism of action through adipose tissue beta-3 adrenergic signaling pathways, theoretical interactions with beta-blockers are worth noting - compounds that block adrenergic receptors could theoretically attenuate AOD-9604's downstream effects. Users combining AOD-9604 with insulin, insulin sensitizers, or other compounds affecting glucose metabolism should be aware that even though AOD-9604 does not impair insulin sensitivity on its own, the interaction picture in combination use has not been studied.

AOD-9604 Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

AOD-9604's oral bioavailability is confirmed in pig and rodent pharmacokinetic studies, making it a notable outlier among peptide compounds. The structural basis for this unusual property is the disulfide bridge linking Cys7 and Cys14, combined with the N-terminal tyrosine modification. Together, these features confer resistance to gastric acid and proteolytic degradation that normally destroy peptides before absorption. Following intraperitoneal administration in rodent research models, systemic distribution occurs within approximately 15-30 minutes.

Distribution

AOD-9604 distributes to adipose tissue targets following systemic absorption, consistent with its lipolytic mechanism of action. Intra-articular injection data confirms tissue-level activity at local joint sites. No blood-brain barrier penetration data is available in published sources.

Half-Life

Plasma half-life is approximately 3-4 minutes, measured via intravenous administration in pig pharmacokinetic models. This is an extremely short half-life. This figure comes from IV pig models - direct measurement in humans across other administration routes has not been published.

Metabolism & Elimination

AOD-9604 is metabolized through standard peptide hydrolysis pathways. Similar metabolic degradation product profiles were observed across oral and intravenous routes in pig models, suggesting the eventual breakdown products are consistent regardless of how the compound enters the system. Specific metabolic enzymes responsible for clearance and the proportional contributions of renal versus hepatic elimination have not been detailed in available research.

Notable data gap: The 3-4 minute half-life figure is derived exclusively from IV pig models. Human pharmacokinetic characterization across oral and subcutaneous routes - the routes most relevant to actual use - has not been published.

Mechanistic Research

Beta-3 Adrenergic Receptor Upregulation in Obese Adipose Tissue (Evidence: Animal - Heffernan et al., 2001, Endocrinology)

In obese mouse models, AOD-9604 restored depressed beta-3 adrenergic receptor RNA expression in white adipose tissue to levels comparable with lean control animals. Activation of beta-3 adrenergic receptors on fat cells initiates a signaling cascade - elevated cyclic AMP, activation of Protein Kinase A, phosphorylation of Hormone-Sensitive Lipase - that drives triglyceride breakdown. Knockout mouse experiments established that long-term weight loss effects require intact beta-3 adrenergic receptor signaling, but acute single-dose increases in fat oxidation still occurred in receptor-knockout animals. This dissociation confirms that beta-3 AR upregulation is a downstream consequence of AOD-9604 signaling, not the compound's direct binding target.

AMPK Pathway Involvement and Fat Oxidation (Evidence: Animal models)

Lipolytic effects in rodent adipose tissue involve AMP-activated protein kinase (AMPK) pathways - a central cellular energy-sensing system. AMPK activation shifts cells from energy storage toward energy utilization, suppressing fat synthesis and promoting fat oxidation simultaneously. The involvement of AMPK adds a layer to the mechanistic picture beyond simple adrenergic signaling, suggesting AOD-9604 may interface with broader metabolic switching machinery rather than a single receptor pathway. Brown adipose tissue uncoupling - where fat tissue generates heat rather than ATP - has been proposed as a contributing mechanism to the observed increases in whole-body energy expenditure.

Direct Lipolysis in Human Adipose Tissue (Evidence: Ex vivo human tissue - Heffernan et al., 2001, Endocrinology)

Ex vivo studies using human adipose tissue samples demonstrated a threefold increase in glycerol release following AOD-9604 exposure - glycerol being a direct quantitative marker of triglyceride breakdown. This finding is notable because it moves the lipolytic evidence from animal models to actual human tissue, providing direct biological confirmation that the fat-breakdown mechanism operates in human fat cells. The preferential activity in obese adipose tissue over lean tissue observed in animal models adds further specificity to the mechanism.

Condition-Focused Research

Obesity and Weight Management {#research-obesity}

The Phase IIa 12-week randomized controlled trial tested oral AOD-9604 at multiple doses in adults with obesity. The 1 mg/day group achieved an average weight loss of 2.6 kg versus 0.8 kg in the placebo group, with preferential reduction in abdominal and visceral fat. No adverse changes in IGF-1, glucose tolerance, or insulin sensitivity were detected in any dose group. The finding that 10 mg/day produced less weight loss than 1 mg/day represents a paradoxical inverse dose-response relationship that has not been fully explained in published literature. (Evidence: Moderate - human RCT - Heffernan et al., 2001, Endocrinology)

The Phase III 24-week randomized controlled trial enrolled 502 subjects with obesity, using oral AOD-9604 alongside intensive diet and exercise intervention. This trial did not demonstrate statistically significant weight loss versus placebo. The Phase III failure is the central clinical limitation on AOD-9604's weight management evidence and the reason its pharmaceutical development was terminated in 2007. The intensive lifestyle intervention in both arms likely compressed the detectable peptide-specific effect, but these methodological considerations do not change the clinical outcome. (Evidence: Moderate - human Phase III RCT; primary endpoint failed - Stier et al., 2013, Regulatory Toxicology and Pharmacology)

Preclinical Fat Loss Models {#research-preclinical}

Obese Zucker rats treated with oral AOD-9604 at 500 mcg/kg for 19 days experienced approximately 50% reduction in weight gain compared to untreated controls, with confirmed increases in adipose tissue lipolytic activity. Beta-3 adrenergic receptor studies in ob/ob mice documented restoration of depressed receptor expression to lean-animal levels following AOD-9604 treatment, with improved body composition outcomes at effective doses. These animal model findings provided the mechanistic foundation and dose rationale for human trial design. (Evidence: Animal - Ng et al., 2000, Hormone Research)

Joint and Cartilage Regeneration {#research-joint}

Kwon and Park (2015) induced knee osteoarthritis in New Zealand White rabbits using collagenase injection, then administered AOD-9604 intra-articularly at 0.25 mg per joint. Treated animals showed significantly improved cartilage morphology and histopathological scores versus saline controls, along with reduced lameness duration. When AOD-9604 was combined with hyaluronic acid, outcomes were superior to either treatment alone - suggesting a possible synergistic effect with standard osteoarthritis interventions. No human clinical data exists for this application. (Evidence: Preliminary - animal model - Kwon & Park, 2015, Annals of Clinical and Laboratory Science)

In Vitro Stem Cell and Chondrocyte Research {#research-invitro}

Cell culture studies demonstrated that AOD-9604 promotes differentiation of adipose-derived mesenchymal stem cells into osteogenic (bone-forming) lineages and increases proteoglycan and collagen synthesis in bovine chondrocyte cultures. Enhanced myoblast differentiation was also observed. These findings were reported by Kim et al. (2010) in the Journal of Korean Medical Science and represent the in vitro mechanistic foundation for the cartilage and regenerative research direction that emerged after the obesity program was discontinued. The specific receptor or intracellular pathway mediating these effects has not been characterized. (Evidence: In vitro - Kim et al., 2010, Journal of Korean Medical Science)

Safety and Tolerability Research

The clinical safety database for AOD-9604 is unusually robust for a research-stage peptide compound. Stier et al. (2013) published a comprehensive review of safety data across six randomized, double-blind, placebo-controlled trials involving approximately 900 human subjects with a maximum trial duration of 24 weeks. No serious adverse events were attributed to AOD-9604 across this database. No treatment-related withdrawals occurred in any trial. Immunogenicity testing found no evidence of antibody development, which is a meaningful safety finding given the compound's non-native sequence elements. The overall safety profile in clinical review was described as indistinguishable from placebo. (Evidence: Human - comprehensive clinical review - Stier et al., 2013, Regulatory Toxicology and Pharmacology)

Research Limitations

AOD-9604's evidence base has a specific and important shape: substantial human trial data for safety, a mixed picture for efficacy, and early-stage data for its newer regenerative applications. The primary endpoint failure in the 502-subject Phase III RCT is the defining gap - it means AOD-9604 has never demonstrated statistically significant weight loss in a large, well-powered human trial. The Phase IIa signal was real but did not replicate at scale. No human clinical trials have been conducted for joint or cartilage applications; that evidence is entirely animal and in vitro. The compound's primary receptor binding target has never been identified despite extensive mechanistic research. Human pharmacokinetic data across subcutaneous and oral routes is absent - the 3-4 minute half-life figure comes from IV pig models only. Long-term safety data beyond 24 weeks does not exist. No trials have been conducted in populations with significant comorbidities such as hepatic impairment, renal dysfunction, or type 2 diabetes.

Is AOD-9604 Legal? Regulatory & Sports Status

FDA status: Not approved for any human use indication. AOD-9604's pharmaceutical development was abandoned in 2007 following the Phase III failure, before any FDA approval application was filed. It is classified as a research compound in the United States. In 2023-2024, the FDA issued guidance regarding compounded peptides that affects the regulatory landscape for multiple compounds in this class - the current status of AOD-9604 with respect to compounding pharmacy regulations is subject to ongoing regulatory interpretation and users should verify current guidance at the time of use.

Research Use Classification: In most jurisdictions, AOD-9604 is available as a research chemical not approved for human therapeutic use. The compound has never been registered as a pharmaceutical product in any country.

WADA / USADA status: Explicitly prohibited in competitive sport. WADA released a specific prohibition statement in 2013 classifying AOD-9604 under peptide hormones and related substances on the Prohibited List. The ban applies regardless of dose, route, or stated purpose. Any competitive athlete using AOD-9604 faces a doping violation under WADA and USADA rules.

Country-specific notes: AOD-9604 was developed in Australia at Monash University, but it is not TGA-approved as a pharmaceutical in Australia. No country has registered it as an approved medicinal product. Regulatory classification as a research chemical, prescription compound, or controlled substance varies by jurisdiction - users outside the U.S. should verify the specific rules governing peptide compounds in their country.

Detection: A specific WADA testing protocol for AOD-9604 was established following the 2013 ban. Detection windows are not publicly specified in available research literature, which is standard practice to avoid providing doping evasion guidance. The compound is considered detectable by anti-doping agencies.

AOD-9604 vs. Alternatives

Commonly Paired With - Synergistic Stacks

• AOD-9604 + BPC-157: One of the more commonly documented stacks in community protocols, pairing AOD-9604's fat metabolism focus with BPC-157's tissue repair and gut healing properties. The rationale is complementary mechanisms - fat loss support alongside systemic recovery. No published combination data exists; the stack is community-documented.
• AOD-9604 + CJC-1295 / Ipamorelin: Pairing with growth hormone-releasing peptides is documented in community protocols targeting body recomposition. The logic is that AOD-9604 handles fat-specific targeting while CJC-1295 or Ipamorelin stimulates natural GH pulses for anabolic support. This combination requires careful consideration given the different regulatory profiles - AOD-9604 is WADA banned, and GH secretagogues have their own prohibited status considerations.
• AOD-9604 + Hyaluronic Acid (intra-articular): Specifically relevant to joint research applications. The Kwon and Park (2015) rabbit osteoarthritis study demonstrated superior outcomes when AOD-9604 was combined with hyaluronic acid compared to either agent alone, suggesting a potential synergistic effect on cartilage regeneration.

Alternatives - When Another Peptide May Be Considered

Fragment 176-191 (unmodified) The native hGH C-terminal fragment, without the N-terminal tyrosine modification that defines AOD-9604. Some research protocols use this unmodified fragment for comparative purposes. The N-terminal tyrosine addition in AOD-9604 confers structural stability advantages and enables oral bioavailability - the unmodified fragment does not share these properties. For metabolic research comparing the native sequence to the modified version, this is a relevant alternative to consider.

Tesamorelin A GHRH analog approved by the FDA for HIV-associated lipodystrophy that reduces visceral fat through a growth hormone-stimulating mechanism. Unlike AOD-9604, Tesamorelin works by stimulating the pituitary to release more growth hormone, which means it does affect IGF-1 levels. It is an option for individuals where a GH-based approach is clinically indicated and managed, but carries the metabolic and hormonal considerations that AOD-9604 was specifically designed to avoid.

Semaglutide and GLP-1 Receptor Agonists GLP-1 agonists like semaglutide operate through a fundamentally different mechanism - appetite regulation, gastric emptying, and insulin sensitization - versus AOD-9604's direct lipolytic mechanism. They are FDA-approved for obesity and type 2 diabetes, carry a far larger human evidence base, and have demonstrated substantially greater weight loss in clinical trials. For someone whose primary goal is clinically significant weight reduction with a robust human data foundation, GLP-1 agonists represent the current evidence-based standard of care. AOD-9604 is a research compound with a mechanistically distinct and IGF-1-independent profile.

Comparison table:

Build Your Protocol - MPP CTA

FAQs

What is AOD-9604?

AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal region of human growth hormone. It was developed by researchers at Monash University in Australia with the goal of isolating growth hormone's fat-burning properties while removing its broader hormonal effects on growth promotion and blood sugar regulation. It was studied in six randomized controlled human trials as a potential anti-obesity drug before pharmaceutical development was discontinued in 2007.

What does AOD-9604 do?

AOD-9604 stimulates the breakdown of stored fat in adipose tissue, inhibits the formation of new fat from dietary carbohydrates, and increases fat oxidation - all without raising IGF-1 levels, affecting blood glucose, or promoting tissue growth. In research settings, it has also been studied for cartilage and joint regeneration applications, where early animal and in vitro findings suggest effects on collagen and proteoglycan production.

How long does AOD-9604 take to work?

Based on clinical trial data, meaningful body composition changes from AOD-9604 were observed over a 12-week period in the Phase IIa trial - not within days or a few weeks. Users in tracked protocols typically report first noticing changes in the 6-10 week range. Timelines vary based on dose, route of administration, diet, and individual metabolic factors.

What is the typical dose of AOD-9604?

The dose showing the strongest weight loss signal in human clinical trials was 1 mg per day taken orally. In subcutaneous injection protocols, the commonly used range spans 250 mcg to 1 mg daily. A critical and unusual feature of AOD-9604 is that higher doses are not more effective - the 10 mg/day dose in the Phase IIa trial performed worse than 1 mg/day. Exact protocols depend on individual health factors and goals; MyPeptidePal builds personalized protocols based on your specific situation.

Is AOD-9604 legal?

AOD-9604 is not approved for human therapeutic use in any country and is classified as a research compound in most jurisdictions. It is explicitly banned in competitive sport under the WADA Prohibited List since 2013, categorized under peptide hormones and related substances. Athletes subject to anti-doping rules should not use this compound. Non-athletes should verify the legal classification of research peptides in their specific country before use.

Can AOD-9604 be taken orally?

Yes - AOD-9604 is one of the few peptides with confirmed oral bioavailability. Most peptides are destroyed by gastric acid before they can be absorbed, but AOD-9604's disulfide bridge structure and N-terminal tyrosine modification make it resistant to gastric acid degradation. Oral administration was used in both the Phase IIa and Phase III human clinical trials. Despite this, subcutaneous injection is the more commonly used route in current research protocols because it offers more precise dose control.

Why did AOD-9604 fail its Phase III trial if it worked in Phase IIa?

The Phase III trial enrolled 502 subjects and ran for 24 weeks, with intensive diet and exercise intervention for all participants - including the placebo group. When everyone is dieting and exercising intensively, the lifestyle intervention itself produces weight loss that can statistically mask a modest peptide-specific effect. The Phase IIa trial at 12 weeks showed a real signal at 1 mg/day, but the larger, longer trial could not separate that signal from the background noise of intensive lifestyle change. The Phase III failure does not prove the peptide has no effect - but it does mean AOD-9604 has not passed the standard bar for clinical efficacy that drug approval requires.

Does AOD-9604 affect growth hormone or IGF-1 levels?

No - this is one of AOD-9604's defining characteristics. The compound does not stimulate growth hormone receptors and produces no measurable changes in IGF-1 levels at any dose tested in human clinical trials. This was confirmed across all six controlled trials. The absence of IGF-1 elevation is the primary feature distinguishing AOD-9604 from full-length human growth hormone and from growth hormone secretagogues.

Is AOD-9604 the same as hGH Fragment 176-191?

They are closely related but not identical. Both are derived from the C-terminal region of human growth hormone. AOD-9604 has a tyrosine residue added at its N-terminus specifically to improve stability and enable oral bioavailability - this modification is what gives it its distinct properties and separate research identity. The unmodified fragment (176-191) lacks these stability features and does not have documented oral activity. Some sources use the names interchangeably, which is technically imprecise.

Final Thoughts

AOD-9604 occupies an unusual position in the peptide research landscape. It is a compound with a genuinely interesting and well-characterized mechanism - IGF-1-independent lipolysis, lipogenesis inhibition, and fat oxidation through beta-3 adrenergic and AMPK pathways - backed by six randomized controlled human trials and approximately 900 research subjects. That is a more substantial human trial database than most research peptides ever accumulate. At the same time, it is a compound whose flagship clinical application failed. The Phase III trial did not demonstrate statistically significant weight loss versus placebo in 502 subjects over 24 weeks. Both of those facts are true simultaneously, and anyone researching this compound should hold both of them.

The honest picture on evidence: AOD-9604 has a clean safety record, a mechanistically plausible and partially confirmed mechanism, a positive Phase IIa signal that did not replicate at larger scale, and a secondary cartilage research application that is early but genuinely interesting. It is not a compound with a proven clinical weight-loss effect by drug development standards, but it is also not a compound without meaningful human data. The distinction matters. Its WADA-banned status since 2013 is an important legal consideration for any competitive athlete, and its research compound classification across all jurisdictions means it is not a prescribed therapeutic in any standard medical context.

If you are researching AOD-9604 or considering it as part of a protocol, the details matter significantly - dose, route, cycle length, and what else is in the protocol all affect how this compound behaves and what to expect. The broad ranges here give you the research context. MyPeptidePal builds from that foundation into a personalized protocol accounting for your specific health history, goals, and overall approach - in under 60 seconds. That is where the general picture in this article becomes something you can actually act on.

References

1. Heffernan, M., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., & Ng, F. M. (2001). AOD9604: An anti-obesity drug with some growth hormone secretagogue properties. Endocrinology, 142(12), 5182-5189.

2. Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278.

3. Stier, H., Vos, E., & Kenley, D. (2013). Safety and tolerability of the anti-obesity drug candidate AOD9604 in healthy adults. Regulatory Toxicology and Pharmacology, 65(2), 215-221.

4. Kwon, D. R., & Park, G. Y. (2015). Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbits with collagenase-induced osteoarthritis. Annals of Clinical and Laboratory Science, 45(4), 426-432.

5. Kim, J. H., Lee, S. K., & Kim, S. J. (2010). Effect of AOD9604 on the chondrogenic differentiation of adipose tissue-derived mesenchymal stem cells. Journal of Korean Medical Science, 25(5), 776-780.